ABSTRACT
INTRODUCTION
Antinuclear antibodies (ANA) are essential autoantibodies for screening and diagnosis of systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (SLE), as well as non-rheumatic autoimmune diseases. [1] [2] [3] [4] [5] Certain specific antibodies are included in the diagnostic criteria for certain specific diseases. [6] [7] [8] [9] Indirect immunofluorescence (IIF) assay is the gold standard method that is most commonly used for detection of ANA. 10 
IIF uses Hep-2 cells as
Original Article SMJ a substrate, which provides almost all of the antigens that are required for ANA testing. However, enzyme immunoassay (EIA) is more rapid and simple than IIF for detecting ANA. EIA contains disease-relevant native or recombinant antigens that are coated on a microtiter plate. IIF using Hep-2 cells could yield a false-negative result for anti-Ro and anti-Jo-1 antibodies, while EIA could detect them. 11, 12 However, EIA has been associated with both false-positive and false-negative results. 13 During 2010, the Clinical Pathology Laboratory at Siriraj Hospital implemented a protocol that calls for IIF to be used for initial screening of ANA. In cases of negative result by IIF, secondary screening is performed using EIA. We observed that among sera positive for ANA by EIA, some sera samples were positive and some were negative for specific antibodies subsequently requested by the physician.
Accordingly, the aim of this study was to investigate the predictive value of positive EIA for detection of specific autoantibodies in sera negative for ANA by IIF, but positive for ANA by EIA. The secondary objective was to determine and report the prevalence and clinical findings of certain antibodies.
MATERIALS AND METHODS

Patient sera
Sera negative for ANA by IIF, but positive for ANA by EIA were randomly selected from stored sera sent to the Clinical Pathology Laboratory at Siriraj Hospital for ANA testing during 2010. Sera were stored at -20°C before analysis. Siriraj Hospital is Thailand's largest national tertiary referral center.
Medical records of patients whose sera were included in this study were reviewed. Clinical findings at the time of blood sampling for ANA testing and at 5 years after sampling were obtained and recorded.
The protocol for this study was approved by the Siriraj Institutional Review Board (SIRB), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (Si 211/2557).
IIF assay
IIF assay was performed using a Mosaic HEp-20-10/Liver (Monkey) Kit (Euroimmun AG, Lübeck, Germany). Briefly, sera were diluted to 1:100 and then incubated with Hep-20-10 cells. The Hep-20-10 cells contained an increased spectrum of Hep-2 cells in the mitotic phase. After staining with fluorescent conjugate, slides were visualized under a fluorescent microscope at 400x. Fluorescence intensity was compared with that of the end-point positive control. Fluorescence intensity equal to or greater than the fluorescence intensity of the end-point positive control was considered a positive result.
EIA testing
EIA testing was performed using an IMTEC-ANA Screen Kit (Human Diagnostics, Wiesbaden, Germany). The microtiter strips came coated with HeLa cell nuclei. Sera were diluted to 1:101 before being added to the plates. The manufacturer defined any value above 55 U/ml as being a positive result.
Antigen-specific assays
Line immunoassay (LIA) was performed using an IMTEC-ANA-LIA Kit (Human Diagnostics). The strips contain the following antigens: nucleosomes, histones, SmD1, nRNP, SSA/Ro60, Ro52, SSB/La, Scl-70, CENP-B, Jo-1, and ribosomal P proteins (Rib-P). Sera showing positive reactivity on the Human Diagnostics LIA were tested again using a EUROLINE ANA Profile 3 Kit (Euroimmun AG) to confirm the result. The strips in that kit contain the following antigens: nRNP, Sm, SSA/Ro60, Ro-52, SSB/La, Scl-70, PM/Scl, Jo-1, CENP-B, PCNA, dsDNA, nucleosomes, histones, Rib-P, and AMA M2. Sera were diluted to 1:101 before incubation with the strips. Positive reactivity on both LIA kits for at least 1 identical antibody (Ab) type was considered a positive result.
Statistical analysis
All data were collected and analyzed using Microsoft Excel 2016 spreadsheet software (Microsoft Corporation, Redmond, WA, USA). Rate of positive or negative LIA, predictive value of positive EIA, prevalence of each specific antibody, and 95% confidence interval (CI) were calculated.
RESULTS
Eighty sera that tested negative for ANA by IIF, but that tested positive for ANA by EIA were included. An overview of LIA results from both LIA test kits is shown in Fig 1. Seven sera with positive LIA by only the Human Diagnostics LIA (samples 31-37), and 2 sera positive for different antibody types using either the Human Diagnostics LIA or the Euroimmun LIA (samples 29-30) were considered negative LIA (Table 1) . Therefore, 28 sera (35%) were considered positive LIA (samples 1-28).
The manufacturer's recommended cut-off value of 55 U/mL could not discriminate positive from negative LIA (Fig. 2) . Using the LIA result as a reference standard, the Table 2 .
The most prevalent antibodies were anti-SSA/Ro60 (64.3%, 95% CI: 46.5-82.0%), anti-Ro52 (25%, 95% CI:
9.0-41.0%), and anti-SSB/La (10.7%, 95% CI: 0-22.2%) ( Table 1) . A diagnosis of SARD was established in 7 of 28 patients (25%) at the time of blood sampling. Four patients (14.3%) were diagnosed with non-rheumatic autoimmune disease. Seventeen patients had insufficient evidence for diagnosing autoimmune disease (60.7%).
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DISCUSSION
The present study set forth to investigate for specific antibodies in sera negative for ANA by IIF, but positive for ANA by EIA. We found a higher rate of positive specific antibodies than previous study (35% vs. 16.9%). 14 Compared to previous studies that performed antigenspecific assay in all IIF-ANA negative sera and who found a rate of positivity of 0.7-14% [15] [16] [17] , we demonstrated that screening with EIA-ANA before performing antigenspecific assay in IIF-ANA negative sera may increase the probability of identifying specific antibodies.
The manufacturer's recommended cut-off value yielded a low PPV. Even though the EIA value was as high as 250 U/mL, the PPV of 75% was not sufficiently high. Therefore, a positive result from this EIA kit may not be applicable to real-life clinical practice. However, reporting the EIA result along with its specific PPV may provide benefit relative to a decision to request or not request antigen-specific assay.
Similar to previous studies 14, 16 , the most prevalent antibodies identified in this study were anti-SSA/Ro60, anti-Ro52, and anti-SSB/La, and these antibodies have been recognized as being associated with Sjogren syndrome and SLE. 18 Anti-SSA/Ro60 was shown to have association with both subacute cutaneous lupus erythematosus 19 and neonatal lupus erythematosus. 20, 21 In the present study, a large proportion of patients with positive LIA were not diagnosed as autoimmune disease by the 5-year follow-up. However, the presence of autoantibodies often portends the development of disease that does not fully clinically manifest until years into the future. Anti-SSA/ Ro60 could be detected before the onset of symptoms and diagnosis of SLE at intervals as long as 9.1 and 10.4 years, respectively. 22, 23 This study has some mentionable limitations. First and consistent with the retrospective nature of this study, some data was missing or incomplete. Second, the number of included samples was relatively small. Third, random samples were selected from routine ANA testing; therefore, our findings may not be generalizable to patients tested in specialized clinic. Fourth and last, we investigated only one EIA kit that uses HeLa cell nuclear extract, which may be different from other EIA kits that use different combinations of defined native or recombinant antigens.
CONCLUSION
EIA testing in IIF-ANA negative sera yielded a chance to detect antinuclear antibodies. However, the poor PPV of EIA may have low benefit in real-life clinical practice. Anti-SSA/Ro60 was the most prevalent antibody detected. A high proportion of LIA-ANA positive patients were not diagnosed as autoimmune disease at the time of antibody detection. 
